Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

Stopped The study was never submitted to IRB or approved, due to feasibility issues

Conditions

• Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
• Respiratory Failure
• Sars-CoV2

Interventions

• DRUG: Rapamycin
• DRUG: Placebo

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

• [object Object]